TheraSphere Y90
Closed Special Notice Posted
- Solicitation number
- W81K0022Q0006
- Agency
- Medical Command Department of the Army, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- Place of performance
- Jbsa Ft Sam Houston, Texas 78234, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Special Notice from the Department of the Army Medical Command indicates intent to award a sole source contract to Boston Scientific for TheraSphere doses, an FDA-approved liver cancer therapy. TheraSphere consists of glass microspheres containing radioactive Y90 and is the only FDA-approved treatment for primary liver cancer when appropriately positioned hepatic arterial catheters can be used.
The Special Notice provides details of the planned sole source award to Boston Scientific under FAR 13.501(a)(1)(ii) for supplies needed to treat liver cancer patients in the Regional Health Command Central. Interested parties have until January 7, 2022 at 11:00AM CST to submit capability statements for consideration, though award will be made to Boston Scientific on or after January 10, 2022. The applicable NAICS code is 325412 for pharmaceutical preparation manufacturing and the size standard is 1,250 employees. Responses must meet the salient characteristics stated and any proprietary information within submissions must be appropriately marked.
Notice text
Notice of Intent to Award Sole Source.
The Regional Health Contracting Office-Central, JBSA - Fort Sam Houston, Texas intends to award a Firm-Fixed-Price sole source contract to Boston Scientific under the authority of Federal Acquisition Regulation (FAR) 13.501(a)(1)(ii), sole source, for the FDA approved TheraSphere doses product, which is a liver cancer therapy that consists of millions of small glass microspheres containing radioactive Y90 and who has the only FDA approved treatment for Primary liver cancer. TheraSphere is indicated for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. These supplies are needed to treat liver cancer patients in the Regional Health Command Central (RHC-C).
The applicable NAICS code for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Small Business Size Standard is 1,250 employees. Award will be made on or after 10 January 2022.
The solicitation number is W81K0022Q0006, and is generated for the purposes of posting this notice. THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. All responses received, to include capability statements, and meet the salient characteristics as stated below by 7 January 2022-11:00AM CST of the posting of this notice will be considered by the Government. A determination by the Government not to compete the interim purchase order based upon responses to this notice is solely within the discretion of the Government. Interested sources who submit data are responsible for appropriately marking information if it is proprietary in nature.
Roland Jasso
Roland.jasso.civ@mail.mil
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity